UNSPSC 51283600: Rifamycin antibacterials

This classification denotes a group of anti-bacterial agents characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known anti-bacterial agents, and they have been isolated from fermentation broths of streptomyces mediterranei.

UNSPSC 51283600 Rifamycin antibacterials is a Class code, but the recent state and local solicitations tagged under it show minimal alignment with rifamycin-specific procurement. The code nominally describes a single antibiotic drug class, yet the opportunities posted under this code encompass naloxone and drug deactivation systems, medical and first aid supplies for fire rescue operations, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program capability assessments. None of these solicitations explicitly reference rifamycins or narrow-spectrum antibiotic procurement. The mismatch suggests that state and local procurement offices are applying this code to broader pharmaceutical and medical supply categories, or that the tagging reflects administrative classification practices that diverge from the code's strict pharmaceutical taxonomy. The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (MMCAP). No pattern of repeat buyers emerges from the recent activity under this code.

Geographic spread centers on Florida, Texas, and Minnesota, with additional participation from Oregon through MMCAP's cooperative purchasing vehicle. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026 with response due July 26, 2023; the City of Tampa's IFB for 169 line items of medical and first aid supplies for fire rescue operations, posted March 25, 2026 with response due March 13, 2026, designated exclusively for certified Small Local Business Enterprises with a 5 percent bid discount and an estimated contract value of $700,000; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with response due March 26, 2026, requiring vendors to supply through three authorized wholesalers with an effective date of July 1, 2026. The Texas HHS RFI for direct-to-manufacturer prescriptions (posted April 3, 2026) reflects early-stage market intelligence gathering rather than a formal competitive procurement. This code shows substantial procurement activity, but the scope divergence from rifamycin-specific products makes direct relevance uncertain.